At a glance
- Originator Shire Pharmaceuticals Group
- Class Cytostatic antibiotics
- Mechanism of Action Angiogenesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 05 Jun 2001 BioChem Pharma has been acquired by Shire Pharmaceuticals Group
- 29 May 1997 Preclinical development for Cancer in Canada (Unknown route)